Anti-inflammatory efficacy
Evaluate candidate activity in a selected induced atopic-dermatitis mouse model.
IMMUNOLOGY & INFLAMMATION MODEL
Atopic Dermatitis Mouse Models
Documented atopic-dermatitis platforms include OXA-, DNCB-, FITC-, and MC903-induced mouse models for inflammatory skin-disease pharmacology.
Induction format, treatment route, study window, skin assessment, tissue collection, and biomarker package are selected around the program objective.
MODEL OVERVIEW
Multiple induced mouse formats for atopic dermatitis pharmacology.
The reviewed partner portfolios include several induced atopic-dermatitis models, enabling study design to be matched to candidate mechanism, route of administration, treatment duration, and required skin or biomarker outputs.
Therapeutic areaAtopic dermatitis
SpeciesMouse
Model formatOXA, DNCB, FITC, MC903
Typical useEfficacy, Skin pathology, Biomarkers
TYPICAL APPLICATIONS
What this model can support.
Topical or systemic dosing
Align route and formulation with the intended product profile when technically appropriate.
Skin tissue analysis
Collect protocol-defined skin samples for histology, molecular analysis, or other downstream work.
PK/PD & biomarkers
Integrate exposure, pharmacodynamic, and inflammatory biomarker measurements when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Skin phenotype
Protocol-defined skin-disease and treatment-response assessments.
Histopathology
Skin tissue collection and histology according to the selected protocol.
Biomarkers
Inflammatory or mechanism-linked biomarker measurements selected for the program.
Exposure
Systemic or selected tissue exposure when PK/PD work is incorporated.
Exact induction regimen, mouse strain, treatment window, skin assessment, pathology, and biomarker package are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- OXA, DNCB, FITC, or MC903 model format
- Candidate mechanism
- Topical or systemic dosing strategy
- Treatment timing and duration
- Skin assessment and histology plan
- PK/PD and biomarker requirements
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a Atopic Dermatitis study.Required fields are marked with an asterisk(*).